TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01150877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
Study: NCT05663996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: locally applied to the skin
Description: Applying St John's wort oil locally on the knee three times a day for three weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: locally applied to the skin
Description: Applying olive oil locally on the knee three times a day for three weeks.
Study: NCT03126136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nicom (TM)
Description: Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
Study: NCT03382899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Pegilodecakin plus Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab Alone
Study: NCT00711399

Intervention type: DEVICE
Intervention: PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies
Description: wheeze and cough detection in hospitalized patients.
Study: NCT03800706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.
Study: NCT02110810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin suppository of 100 mg immediately afterwards while still under sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2.6-g suppository of glycerin
Description: to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
Study: NCT03613090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagen-hydroxyapatite scaffold (Syn-Oss)
Description: The aim of this study is to add to the existing body of regenerative endodontics research by providing human radiographic evidence for the healing process which occurs after the placement of a FDA-approved collagen-hydroxyapatite scaffold, in the use of a blood clot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagen Scaffold (Colla-Plug)
Description: Traditionally, endodontic therapy consisted of removing the infected dental pulp from the canal spaces and replacing it with an artificial substitute called gutta percha. Regenerative endodontic research efforts were originally concentrated upon treatment of the immature necrotic tooth whereby stem cells from the bone near the root end were stimulated to grow onto a blood clot scaffold created within the debrided and disinfected canal space. The hope is that the stem cells would differentiate into cells which could potentially replace the lost pulpal tissues, restoring what was lost due to infection.
Study: NCT00559052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIOKASE 16
Description: The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
Study: NCT03827473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Given per standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01044719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime 2g TDS IV
Study: NCT03827473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01044719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime 2g TDS IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime 2g TDS IV
Study: NCT02102269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shoulderlift
Study: NCT02724826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Qigong therapy
Description: Medical qigong

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: Regular exercise
Study: NCT01082224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodinated contrast dye
Description: iodinated Radiocontrast dye for imaging enhancement

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: motexafin gadolinium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eovist-enhanced MRI
Description: A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
Study: NCT03079388

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ready-to-use-supplementary food
Description: Specially formulated supplementary food for pregnancy

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Corn-soy-blend
Description: Standard of care for malnutrition in pregnancy in Sierra Leone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)
Description: Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard intermittent preventive treatment of malaria during pregnancy (IPTp)
Description: Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide-treated mosquito net
Description: An insecticide-treated mosquito net at the time of enrollment into the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide-treated mosquito net
Description: An insecticide-treated mosquito net at the time of enrollment into the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Single dose albendazole 400mg given in the second trimester.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Single dose albendazole 400mg given in the second trimester.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis testing and treatment
Description: Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
Study: NCT00520832

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Microcurrent
Description: Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
Study: NCT00754468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation
Description: Cryo Spray Ablation 4 cycles x 10 seconds treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo Spray Ablation
Description: Cryo Spray Ablation 2 cycles x 20 seconds
Study: NCT00136123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of functional loaded synthetic teeth after placement implants
Description: Placement of functional loaded synthetic teeth after placement implants
Study: NCT01349231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Ketamine (a single 0.5mg intravenously over 40 minutes).
Study: NCT01988220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory retraining

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repeated sensory input
Description: sensory stimulation without attentive learning focus
Study: NCT02424448

Intervention type: PROCEDURE
Intervention: Biopsies, blood and urine samples
Description: Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.~Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken.
Study: NCT02922855

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 0 dollars group
Description: Those assigned to the $0 group will not receive an incentive for visiting their PCP.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50 dollars group
Description: Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 25 dollars group
Description: Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
Study: NCT01624337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHA-piperaquine
Description: Drug: Dihydroartemisinin piperaquine~40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)
Study: NCT03217526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait Training
Description: Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gait Training
Description: Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
Study: NCT03827473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03756974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BX-1
Description: BX-1 (dronabinol), oral solution. All patients enrolled establish their individually tolerable dose by dose Titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of BX-1, oral solution
Study: NCT03643432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise adherence intervention
Description: Before their physiotherapy appointment participants will be given four short questions to answer. Following this the participant will be assessed as normal. As part of the treatment they will be given an exercise programme as standard within physiotherapy. Following this participants will be asked to answer a further seven short questions; depending on the answers to both sets of questions, and on any discussion based on the answers, the physiotherapist will suggest one or more adherence approaches from a list of suggestions. These are; Review of exercise programme; Review of method of delivery; Cues or prompts; Discussion of barriers and problem solving; Motivational interviewing, Decision balance sheets; Behavioural contract; Goal setting review; Monitoring telephone call; Reminders.
Study: NCT02931396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Study: NCT03643432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in usual care will attend physiotherapy sessions as they would have had they not been in the trial.These sessions will include assessment and treatment approaches as given as part of routine care, without including the intervention described above for the 'exercise adherence intervention' arm
Study: NCT02666092

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)

Intervention type: BIOLOGICAL
Intervention: Detection of anti-Anisakis and anti-fish antibodies
Description: Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.

Intervention type: BIOLOGICAL
Intervention: Detection of anti-Anisakis and anti-fish antibodies
Description: Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
Study: NCT02908958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
Study: NCT00595699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: 10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT02075762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transbronchial biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprobe biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VATS biopsy
Study: NCT02179515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-brachyury- TRICOM
Description: It is an active cancer immunotherapy administered via subcutaneous injection.
Study: NCT01798134

Intervention type: DEVICE
Group type: OTHER
Intervention: TANDEM™
Study: NCT02259413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Rehabilitation
Description: This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 26 weeks
Study: NCT02288767

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional arterial blood pressure monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stroke volume variation monitoring with arterial blood pressure monitoring
Study: NCT03532945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Glass-Ceramic Spacer
Study: NCT00497588

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT03532945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium cage
Study: NCT01151995

Intervention type: OTHER
Intervention: Remote source document verification
Description: Remote access to electronic medical records of the 5 participating sites

Intervention type: OTHER
Intervention: On-site source document verification
Description: Study monitor will perform on-site source document verification during routine visit to the five participating sites
Study: NCT04302610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchange mask (ColdAvenger® expedition balaclava, USA,
Description: A heat and moisture exchange mask will warm and humidify inspired air and therefore reduce airway heat and water loss during exercise. This will potentially reduce the incidence of and severity of EIB and may also have the potential to decrease the incidence of cough amongst athletes engaging in sports in cold dry environments

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Same as the HME mask but active HME parts withdrawn from devices and multiple holes made in mouth piece to improve ventilation of mask and reduce HME ability of mask
Study: NCT04591912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mind. body. voice
Description: The mbv program consists of 10 weekly sessions that include a variety of practices, including: cognitive dissonance exercises, contemplative practices, guided discussion and community building.
Study: NCT04762108

Intervention type: OTHER
Intervention: Standard of care
Description: Patients will be given standard of care as per their clinical needs
Study: NCT03073655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Verbal Input
Description: The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral Verbal Input
Description: The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Verbal Input
Description: The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
Study: NCT00497588

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Study: NCT00828919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axitinib
Description: BID oral tablets. dose of axitinib (AG 013736) will be the same as they were taking in the previous trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: BID oral Capsules. Dose of crizotinib will be the same taken in previous axitinib trial.
Study: NCT02413528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inhaler sensor
Description: Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application for asthma adherence
Description: Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
Study: NCT03394716

Intervention type: RADIATION
Intervention: Radiotherapy
Description: standard radiotherapy treatment with 1-3 extra MRIs
Study: NCT04402606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation on skin toxicities
Description: Measurements will be carried out using specific tools, such as the cutaneous ultrasound system (measurement of the skin layers thicknesses, the cutometer (measurement of the elasticity of the skin), the corneometer (measurement of the hydration of the skin), the pH meter (measuring the pH of the skin), the colorimeter (measuring the color of the skin), the tewameter (measuring the insensible loss of water), the sebometer (measuring sebum).
Study: NCT05308368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: We will collect ultrasound images during the grasping motion for both groups

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: We will collect ultrasound images during the grasping motion for both groups
Study: NCT02465359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human)
Description: Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
Study: NCT02516774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study: NCT04774224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baricitinib
Description: Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. Two-thirds of participants will receive Baricitinib.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one tablet of study drug per day for 48 weeks, and will be followed up for 48 weeks after study drug treatment has finished. One-third of participants will receive Placebo.
Study: NCT01624337

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00914485

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Provider Communication Skills Training
Description: Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity.
Study: NCT04344158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105 Injection
Description: AK105 200mg intravenously (IV) on day 1 of each 21-day cycle.